Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Kadimastem to Collaborate with Merck Serono

Published: Tuesday, August 12, 2014
Last Updated: Tuesday, August 12, 2014
Bookmark and Share
Collaboration agreement to advance combined efforts in neurodegenerative disease area.

Kadimastem reports that it has signed a collaboration agreement with Merck to carry out drug screening in the neurodegenerative diseases space for multiple sclerosis (MS), and potential other neurodegenerative diseases. Kadimastem will utilize its unique platform for Merck Serono, the biopharmaceutical division of Merck, for the screening of new compounds as potential new therapeutics.

Kadimastem has developed a technology to differentiate stem cells into oligodendrocytes, cells required in the brain to produce myelin, the insulation for the neural wiring. In MS, oligodendrocytes are destroyed by the immune system. Kadimastem is also equipped to generate stem cell-derived astrocytes. Astrocytes are neural supporting cells shown to be involved in neurodegenerative diseases.

Within the collaboration, Kadimastem will screen compounds in proprietary assays based on these myelin-producing cells and differentiated nerve supporting cells, with the aim of identifying compounds with potential efficacy in MS, and potential effect in other neurodegenerative diseases.

The transaction is consistent with Kadimastem's strategy to produce short term revenues and to develop closer ties with large international pharmaceutical companies for drug screening projects. Drug-screening will be performed with cells that Kadimastem produces routinely for its own cell-therapy products. Kadimastem’s drug-screening platforms comprising human cells can help to predict the potential a drug will eventually have to impact different cell types including oligodendrocytes.

Yossi Ben-Yossef, Kadimastem's CEO, noted that “the collaboration with Merck strengthens the already fruitful relationship between the two companies and is a vote of confidence by Merck Serono in Kadimastem and its innovative technology. The fact that we recently signed a drug screening contract with another pharmaceutical giant is an indication of the scientific merit and maturity of our technology. This reflects an increased understanding that we have the ability to significantly contribute to the drug development process and to shorten timelines.”

Prof. Michel Revel, Kadimastem’s Chief Scientist, added that “the decision by Merck to sign an agreement with us for drug screening shows the excellence of the technology we have developed for creating myelin-producing cells and nerve-supporting cells. We are convinced that the screening assays we are conducting using these cells are accurate, sensitive, and reproducible. Our technology enables discovery of chemical agents that could lead to a new generation of drugs for treating diseases that seriously damage the central nervous system, such as MS and ALS, amyotrophic lateral sclerosis.”

Upon signing of the agreement, Merck will pay Kadimastem an initial fee, and additional payments which are contingent on the achievement of certain milestones. Further financial details are not disclosed.

The collaboration agreement follows a previous agreement between both companies from 2012, and the signature of a memorandum of understanding in 2013 aimed at utilizing Kadimastem’s screening platform to characterize new compounds that may lead to next generation neurodegenerative disease therapeutics.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Stem Cells Know How to Unwind
Research led by the Babraham Institute with collaborators in the UK, Canada and Japan has revealed a new understanding of how an open genome structure supports the long-term and unrestricted developmental potential in embryonic stem cells.
Growing Stem Cells More Safely
Nurturing stem cells atop a bed of mouse cells works well, but is a non-starter for transplants to patients – Brown University scientists are developing a synthetic bed instead.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Skin Cells Turned into Heart Cells and Brain Cells Using Drugs
In a scientific first, Gladstone researchers have used chemical drugs to convert skin cells into heart cells and brain cells, without adding any external genes.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!